Burroughs Wellcome licenses Navelbine
The semi-synthetic vinca alkaloid vinorelbine from the French firm Pierre Fabre Medicament will be marketed in the U.S. and Canada by B-W under the agreement. The anticancer drug "has shown activity in non-small cell lung cancer and breast cancer in Phase II trials in Europe," the firm said. B-W expects to begin clinicals for lung and breast cancer in early 1990. Fabre has obtained in return certain rights to a future anticancer compound from Wellcome in Europe.
You may also be interested in...
Early results from its novel antiviral are encouraging, but demonstrating life-saving qualities in a short window of time will be tricky.
After federal agencies invested almost $5600m to ensure Cue Health could scale up production, FDA announces the self-administered test will be available OTC. it's the agency's first emergency use authorization for an at-home molecular diagnostic test available nonprescription.
Tezepelumab was among four products that the European Medicines Agency most recently considered for review under its accelerated assessment mechanism.